These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 19759112)

  • 1. Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET.
    Tsujikawa T; Yoshida Y; Kudo T; Kiyono Y; Kurokawa T; Kobayashi M; Tsuchida T; Fujibayashi Y; Kotsuji F; Okazawa H
    J Nucl Med; 2009 Oct; 50(10):1598-604. PubMed ID: 19759112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-[¹⁸F]fluoro-17β-oestradiol PET.
    Tsujikawa T; Yoshida Y; Kiyono Y; Kurokawa T; Kudo T; Fujibayashi Y; Kotsuji F; Okazawa H
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):37-45. PubMed ID: 20717823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of 16α-
    Yamada S; Tsuyoshi H; Yamamoto M; Tsujikawa T; Kiyono Y; Okazawa H; Yoshida Y
    J Nucl Med; 2021 May; 62(5):636-642. PubMed ID: 33008930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uterine tumors: pathophysiologic imaging with 16alpha-[18F]fluoro-17beta-estradiol and 18F fluorodeoxyglucose PET--initial experience.
    Tsujikawa T; Yoshida Y; Mori T; Kurokawa T; Fujibayashi Y; Kotsuji F; Okazawa H
    Radiology; 2008 Aug; 248(2):599-605. PubMed ID: 18539894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis.
    Zhao Z; Yoshida Y; Kurokawa T; Kiyono Y; Mori T; Okazawa H
    J Nucl Med; 2013 Apr; 54(4):499-506. PubMed ID: 23471314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients.
    Husby JA; Reitan BC; Biermann M; Trovik J; Bjørge L; Magnussen IJ; Salvesen ØO; Salvesen HB; Haldorsen IS
    J Nucl Med; 2015 Aug; 56(8):1191-8. PubMed ID: 26045311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinctive FDG and FES accumulation pattern of two tamoxifen-treated patients with endometrial hyperplasia.
    Tsujikawa T; Okazawa H; Yoshida Y; Mori T; Kobayashi M; Tsuchida T; Fujibayashi Y
    Ann Nucl Med; 2008 Jan; 22(1):73-7. PubMed ID: 18250990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT.
    van Kruchten M; de Vries EF; Arts HJ; Jager NM; Bongaerts AH; Glaudemans AW; Hollema H; de Vries EG; Hospers GA; Reyners AK
    J Nucl Med; 2015 Jan; 56(1):50-5. PubMed ID: 25476534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative risk stratification using (18)F-FDG PET/CT in women with endometrial cancer.
    Lee HJ; Ahn BC; Hong CM; Song BI; Kim HW; Kang S; Jeong SY; Lee SW; Lee J
    Nuklearmedizin; 2011; 50(5):204-13. PubMed ID: 21727990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
    Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
    Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.
    Gemignani ML; Patil S; Seshan VE; Sampson M; Humm JL; Lewis JS; Brogi E; Larson SM; Morrow M; Pandit-Taskar N
    J Nucl Med; 2013 Oct; 54(10):1697-702. PubMed ID: 23970364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
    Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDG-PET/MRI with high-resolution DWI characterises the distinct phenotypes of endometrial cancer.
    Tsuyoshi H; Tsujikawa T; Yamada S; Chino Y; Shinagawa A; Kurokawa T; Okazawa H; Yoshida Y
    Clin Radiol; 2020 Mar; 75(3):209-215. PubMed ID: 31785782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
    Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
    J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The positron emission tomography with F18 17beta-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer.
    Yoshida Y; Kurokawa T; Sawamura Y; Shinagawa A; Okazawa H; Fujibayashi Y; Kotsuji F
    Gynecol Oncol; 2007 Mar; 104(3):764-6. PubMed ID: 17156828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of lymph node-to-primary tumor standardized uptake value ratio in endometrioid endometrial carcinoma.
    Chung HH; Cheon GJ; Kim JW; Park NH; Song YS
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):47-55. PubMed ID: 28828510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
    Dehdashti F; Mortimer JE; Siegel BA; Griffeth LK; Bonasera TJ; Fusselman MJ; Detert DD; Cutler PD; Katzenellenbogen JA; Welch MJ
    J Nucl Med; 1995 Oct; 36(10):1766-74. PubMed ID: 7562040
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Paquette M; Espinosa-Bentancourt E; Lavallée É; Phoenix S; Lapointe-Milot K; Bessette P; Guérin B; Turcotte ÉE
    J Nucl Med; 2022 May; 63(5):702-707. PubMed ID: 34413142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-
    Kalshetty A; Basu S
    PET Clin; 2018 Apr; 13(2):239-248. PubMed ID: 29482752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.